Contra-indicated in patients with a history of angioedema related to previous treatment with an ACE inhibitor, or a history of hereditary or idiopathic angioedema.
- TRADE NAMES: Altace (Monarch); Tritace (Sanofi-Aventis)
- INDICATIONS: Hypertension
- CLASS: Angiotensin-converting enzyme (ACE) inhibitor, Antihypertensive, Vasodilator
- HALF-LIFE: 2–17 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Alcohol, Aldesleukin, Allopurinol, Alpha blockers, Alprostadil, Amifostine, Amiloride, Angiotensin II receptor antagonists, Antacids, Antihypertensives, Antipsychotics, Azathioprine, Baclofen, Beta blockers, Calcium channel blockers, Clonidine, Corticosteroids, Cyclosporine, Diazoxide, Diuretics, Eplerenone, Estrogens, Everolimus, General anesthetics, Gold & Gold Compounds, Heparins, Hydralazine, Hypotensives, Insulin, Levodopa, Lithium, MAO inhibitors, Metformin, Methyldopa, Minoxidil, Moxisylyte, Moxonidine, Nitrates, Nitroprusside, NSAIDs, Pentoxifylline, Phosphodiasterase 5 inhibitors, Potassium salts, Prostacyclin analogues, Quinine, Rituximab, Sirolimus, Spironolactone, Sulfonylureas, Telmisartan, Temsirolimus, Tizanidine, Tolvaptan, Triamterene, Trimethoprim - PREGNANCY: category C in first trimester; category D in second and third trimesters
- See adverse reactions attributed to class:
FETAL TOXICITY
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Page last updated 02/06/2025
